What is Prime Medicine's research and clinical costs?

Prime Medicine (PRME) reported research and clinical costs of $2.2M in Q1 2026.

How has Prime Medicine's research and clinical costs changed year-over-year?

Prime Medicine's research and clinical costs increased by 11.1% year-over-year, from $1.98M to $2.2M.

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept prme:AccruedResearchAndClinicalCostsCurrent.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Prime Medicine's research and clinical costs?: Prime Medicine (PRME) reported research and clinical costs of $2.2M in Q1 2026.
How has Prime Medicine's research and clinical costs changed year-over-year?: Prime Medicine's research and clinical costs increased by 11.1% year-over-year, from $1.98M to $2.2M.